The prognosis for AML patients with FLT3-ITD mutations is especially poor: FLT3-ITD mutations are detectable in ∼30% of AML patients and are associated with increased resistance to cytarabine, higher relapse rates and shorter median survival times [5–8]. This evidence concerns the gene FLT3 and acute myeloid leukemia.